Alzheimer Disease, Corticobasal Syndrome, Dementia, Dementia With Lewy Bodies, Frontotemporal Dementia, Mild Cognitive Impairment, Parkinson Disease, Primary Progressive Aphasia, Progressive Supranuclear Palsy, Vascular Dementia
Conditions
Keywords
alzheimer's disease, dementia, dementia with lewy bodies, vascular dementia, frontotemporal dementia, mild cognitive impairment, corticobasal syndrome, progressive supranuclear palsy, parkinson's disease, primary progressive aphasia
Brief summary
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).
Detailed description
The goal of this study is to create a model to predict disease progression in patients with mild cognitive impairments and forms of dementia. To accomplish this, the current study will evaluate different tests including: brain imaging (MRI), body fluid samples (blood and cerebrospinal fluid), skin biopsy, cognitive ability, and behavioural questionnaires. The study team hopes that this information can be used to guide diagnosis and better predict disease progression in patients with mild cognitive impairment and and early dementia.
Interventions
None listed
Sponsors
Sunnybrook Health Sciences Centre
Baycrest
Centre for Addiction and Mental Health
Toronto Dementia Research Alliance (TDRA)
University of Toronto
University Health Network, Toronto
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* Possible or probable diagnosis of MCI or early dementia * Age 30-95 * Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits. * Must, in the opinion of the site investigator, be able to complete most study procedures.
Exclusion criteria
* Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive phenotype | Baseline, 6-month follow-up, 1-year follow-up | Change in Toronto Cognitive Assessment (TorCA) scores out of 330, where lower scores indicate increasing cognitive impairments, and individual domains. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of DNA methylation (DNAm) from bloodwork | Baseline | Biological age from DNA methylation (DNAm) collected via bloodwork compared to chronological age. |
| Neurodegenerative protein levels in biofluids and skin biopsy | Baseline, 6-month follow-up, 1-year follow-up | Differences in protein levels between neurodegenerative diagnoses and predictive ability for change in TorCA |
| Structural and Functional Differences between neurodegenerative diseases via MRI of the brain | Baseline | Brain volumes and white matter hyperintensity (WMH) load corresponding to Toronto Cognitive Assessment (TorCA) scores out of 330 where lower scores indicate increasing cognitive impairments. |
Countries
Canada
Contacts
Primary ContactClaudia Clementi, HBSc
Outcome results
None listed